GLPG - Galapagos NV

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
103.18
+0.39 (+0.38%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close102.79
Open104.37
Bid103.96 x 800
Ask104.09 x 100
Day's Range102.44 - 104.69
52 Week Range84.13 - 122.28
Volume102,051
Avg. Volume142,069
Market Cap5.645B
Beta (3Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est125.69
Trade prices are not sourced from all markets
  • Why Galapagos (GLPG) Might Surprise This Earnings Season
    Zacks3 days ago

    Why Galapagos (GLPG) Might Surprise This Earnings Season

    Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • GlobeNewswire15 days ago

    Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)

    PINTA is a randomized, double-blind, placebo-controlled Phase 2 trial investigating a 100 mg once-daily oral dose of GLPG1205 in up to 60 IPF patients. "The first patient dosing in our PINTA Phase 2 trial shows the progress we are making in expanding our IPF franchise," said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos.

  • GlobeNewswire17 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within ICON, Robert Half International, CenterPoint Energy, Galapagos NV, Canadian Pacific Railway, and Mobile Mini — New Research Emphasizes Economic Growth

    NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Simply Wall St.21 days ago

    All You Need To Know About Galapagos NV’s (AMS:GLPG) Financial Health

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Galapagos NV (AMS:GLPG), with a market capitalization of €4.9b, rarely draw their attention from the investing community. Read More...

  • PR Newswire22 days ago

    AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program

    NORTH CHICAGO, Ill., Oct. 24, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (GLPG.NX) to discover and develop new therapies to treat cystic fibrosis (CF). AbbVie's research program aims to develop a best-in-class, triple-combination therapy for patients living with cystic fibrosis. Currently in early clinical development, the program consists of mechanistically distinct drug-candidates, termed "potentiators" and "correctors", which collectively increase the activity of the mutated copies of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that causes CF.

  • GlobeNewswire22 days ago

    Hallmark third quarter 2018 and Annual R&D Update at Galapagos

    First nine months financial results: Group revenues increased by €98.7 million to €205.1 million Operating loss decreased by €9.1 million to €53.5 million Net loss.

  • GlobeNewswire22 days ago

    Galapagos and AbbVie restructure CF collaboration

    AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF. AbbVie will obtain exclusive worldwide rights to the current CF investigational drug candidate portfolio developed by the two companies in the course of the collaboration. AbbVie will be responsible for all future activities and will bear all costs associated with this portfolio in CF going forward.

  • GlobeNewswire22 days ago

    Topline interim results of FALCON trial Part 1 in CF

    The FALCON trial is a phase 1b, multi-center, open-label, non-randomized, multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and efficacy of a novel combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in up to 24 adult patients with CF. The FALCON study's primary objectives include safety and PK. Secondary objectives include changes in pharmacodynamic biomarkers for CFTR activity (sweat chloride concentration and ppFEV1).

  • GlobeNewswire24 days ago

    POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET

    19.15 CET - Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. "The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis," said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences.

  • Business Wire24 days ago

    Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences.

  • GlobeNewswire25 days ago

    PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING

    Chicago, October 21, 2018 0.30 CET- Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis.

  • Business Wire25 days ago

    Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis.

  • 5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage
    InvestorPlace29 days ago

    5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage

    For whatever the reason — the trade war, Federal Reserve or general market malaise — investors have turned on a variety high-momentum shares. The rout in biotech stocks has been pretty severe. The iShares NASDAQ Biotechnology Index (NYSEARCA:IBB) — the broad sector benchmark — is down roughly 5% in October.

  • Simply Wall St.last month

    Do Institutions Own Shares In Galapagos NV (AMS:GLPG)?

    If you want to know who really controls Galapagos NV (AMS:GLPG), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...

  • 3 Biotech Stocks With Major Incoming Catalysts
    Motley Foollast month

    3 Biotech Stocks With Major Incoming Catalysts

    These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.

  • GlobeNewswirelast month

    Galapagos increases share capital through warrant exercises

    Mechelen, Belgium; 3 October 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant.

  • Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV
    Motley Fool2 months ago

    Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV

    Which stock wins in a battle between these two biotechs?

  • GlobeNewswire2 months ago

    Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients

    Galapagos receives a €9 million milestone payment from its collaboration partner Servier for this achievement. ROCCELLA is a multiregional, randomized, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily doses of GLPG1972/S201086 in patients with knee osteoarthritis (OA).  ROCCELLA is planned to recruit approximately 850 patients in countries in Europe, Asia, North America and South America.

  • Is Galapagos NV a Buy Now?
    Motley Fool2 months ago

    Is Galapagos NV a Buy Now?

    It's beginning to look like AbbVie made a big mistake.

  • GlobeNewswire2 months ago

    Galapagos issues new shares as result of public offering

    Mechelen, Belgium; 17 September 2018, 22.01 CET; regulated information- Galapagos NV announces a share capital increase as a result of a public offering of American Depositary Shares.. In accordance with ...

  • GlobeNewswire2 months ago

    Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million

    Galapagos NV (Euronext & NASDAQ: GLPG) announced today the closing of its underwritten public offering of 2,961,373 American Depositary Shares ("ADSs") at a price of $116.50 per ADS, before underwriting discounts, for gross proceeds of €296.2 million. All of the ADSs were offered by Galapagos. Each of the ADSs offered represents the right to receive one ordinary share.

  • GlobeNewswire2 months ago

    Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

    This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, randomized, open-label study in healthy volunteers who will be treated with different single dose levels of MOR106 administered subcutaneously or intravenously. Part 2 is a multiple center, randomized, placebo-controlled, multiple dose study in patients with moderate to severe atopic dermatitis who will be treated subcutaneously for 12 weeks.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 12). Inogen Inc (NASDAQ: INGN ) Kezar Life Sciences Inc ...

  • GlobeNewswire2 months ago

    Galapagos raises $300 million gross proceeds in a U.S. public offering

    Galapagos NV (Euronext & NASDAQ: GLPG) announced today the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares ("ADSs") at $116.50 per ADS, before underwriting discounts. In addition, Galapagos has granted the underwriters an option to purchase up to an additional 386,266 ADSs, representing 15% of the ADSs placed in the offering. The closing of the offering is expected to occur on 17 September 2018, subject to customary closing conditions.

  • GlobeNewswire2 months ago

    Galapagos announces launch of proposed public offering

    Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it intends to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares (ADSs) in a U.S. public offering. In the offering, Galapagos intends to grant the underwriters a 30-day option to purchase additional ADSs, up to 15% of the ADSs placed in the offering. The final price per ADS in the offering will be determined following the bookbuilding process.